



B1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :

C12N 15/53, 15/29, 15/63, 15/70

A1

(11) International Publication Number:

WO 96/09393

(43) International Publication Date:

28 March 1996 (28.03.96)

(21) International Application Number: PCT/US95/11280

(22) International Filing Date: 7 September 1995 (07.09.95)

(30) Priority Data:

310,693

22 September 1994 (22.09.94) US

(60) Parent Application or Grant

(63) Related by Continuation

US

310,693 (CON)

Filed on

22 September 1994 (22.09.94)

(71) Applicants (for all designated States except US): REYNOLDS TECHNOLOGIES, INC. [US/US]; Law Dept. - Patents, Bowman Gray Technical Center, P.O. Box 1487, 950 Reynolds Boulevard, Winston-Salem, NC 27102 (US). BIOSOURCE TECHNOLOGIES, INC. [US/US]; 3333 Vaca Valley Parkway, Vacaville, CA 95688 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HANLEY, Kathleen, M. [US/US]; 309 Saddlebrook Circle, Lewisville, NC 27023 (US). HELLMANN, Gary, Mark [US/US]; 3516 Donegal Drive, Clemmons, NC 27012 (US). NICOLAS,

Olivier [CA/US]; Apartment 1215, 2700 Reynolda Road, Winston-Salem, NC 27106 (US).

(74) Agents: BODENHEIMER, Stephen, M., Jr. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: DNA SEQUENCE ENCODING SQUALENE SYNTHETASE

(57) Abstract

A DNA sequence isolated as a cDNA from a *Nicotiana* species, e.g., *Nicotiana benthamiana*, has a nucleotide sequence represented as SEQ ID NO: 1 which encodes a native squalene synthetase capable of conducting the reductive condensation of two molecules of farnesyl diphosphate to form squalene, constituting the first committed step in sterol biosynthesis in eukaryotes.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**DNA SEQUENCE ENCODING
SQUALENE SYNTHETASE**

Background of the Invention

The present invention relates to genetic engineering, particularly relating to nucleic acid sequences encoding enzymes useful in isoprenoid biosynthesis; and specifically to DNA sequences encoding enzymes involved in catalyzing the biosynthesis of squalene.

Squalene is a 30-carbon triterpene composed of six isoprene units. Squalene is an intermediate in the biosynthesis of sterols, such as, cholesterol. See, Bradfute et al., J. Biol. Chem., Vol. 267, p. 18308 (1992) and Ericsson et al., J. Biol. Chem., Vol. 267, p. 18708 (1992). Squalene synthetase, an enzyme that resides at a branch in sterol biosynthesis, catalyzes the formation of squalene via reductive dimerization of the 15-carbon intermediate farnesyl diphosphate (FPP). This reaction is the first committed step in sterol biosynthesis. Alternatively, FPP may serve as substrate for numerous other prenyltransferases leading to the prenylation of proteins, or to the formation of non-sterol isoprenoids such as dolichols, ubiquinones, and carotenoids. See, Kuswik-Rabiega et al., J. Biol. Chem., Vol. 262, p. 1505 (1987), Summers et al., Gene, Vol. 136, p. 185 (1993); Keller et al., Arch. Biochem. Biophys., Vol. 302, p. 304 (1993); LoGrasso et al., Arch. Biochem.

-2-

Biophys., Vol. 307, p. 193 (1993); McKenzie et al., J. Bio. Chem., Vol. 267, p. 21368 (1992); European Patent Application No. 486,290 and G.B. Patent Application Nos. 2,249,099 and 2,272,442.

5 Squalene synthetase has been studied in mammalian systems, and is considered a key enzyme in the regulation of cholesterol biosynthesis. Thus, squalene synthetase has been studied as a possible target for the design of therapeutics aimed at
10 controlling serum cholesterol levels. See, Robinson et al., Mol. Cell. Biol., Vol.13, p. 2706 (1993). Inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) have been shown to reduce serum cholesterol levels. See, Goldstein et al.,
15 Nature, Vol. 343, p. 425 (1990) and Brown, et al., J. Biol. Chem., Vol. 253, p. 1121 (1978). However, because HMG-CoA reductase mediates an early step in the isoprenoid pathway, the potential exists for the depletion of other key isoprenoids derived from
20 mevalonic acid. Selective inhibition of squalene synthetase on the other hand, should not directly suppress biosynthesis of these non-sterol isoprene metabolites. Consequently, inhibitors of squalene synthetase may have advantages over inhibitors which
25 act further upstream in the pathway. A thorough knowledge of the structure and activity of this enzyme would greatly facilitate the design of specific modulators of squalene synthetase.

Squalene has been found to have useful
30 applications as coatings, as set forth in U.S. Patent Nos. 5,198,254 to Nisperos-Carriedo et al. and 5,284,508 to Shibata et al., in the cosmetics industry, as is set forth in U.S. Patent Nos. 4,699,930 to Suga and 5,116,607 to Jones; and in the pharmaceutical
35 industry, as is set forth in U.S. Patent No. 4,806,352 to Cantrell and 5,260,067 to Zheng Xu. Squalene synthetase inhibitors are set forth in Dufresne et al.,

Tetrahedron, Vol. 48, p. 10221 (1992); Hensens et al.,
Tetrahedron Let., Vol. 34, p. 399 (1993) and U.S.
Patent Nos. 5,250,424 to Bills et al., 5,252,471 to
Byrne et al. and 5,278,067 to Dawson et al..

5 It would be highly desirable to have the
capability to alter those biosynthetic pathways which
involve squalene, particularly in higher plants such as
Solanaceae. As such, it would be desirable to provide
nucleotide sequences that encode enzymes (e.g.,
10 squalene synthetase), which are useful in the
biosynthetic pathway of squalene, and various other
isoprenoids including sterols. In particular, it would
be desirable to provide the nucleotide sequences that
encode squalene synthetase from a higher plant species,
15 such as a Nicotiana species.

Summary of the Invention

The present invention relates to nucleotide
sequences (i.e., DNA and RNA) capable of encoding a
20 polypeptide which has enzymatic activity for producing
squalene. Such a polypeptide is referred to as
squalene synthetase. The DNA is isolated from a plant
(e.g., a higher plant), in particular from a Nicotiana
species (e.g., Nicotiana benthamiana). The nucleotide
25 sequence encodes squalene synthetase, and variants of
that sequence encodes enzymes exhibiting the same
biological activity as squalene synthetase. The
nucleotide sequence corresponds to, or substantially
to, that sequence specified by SEQ ID NO: 1. The
30 nucleotide sequence may be provided in an isolated,
substantially pure form.

In another aspect, the present invention
relates to a polypeptide which may be provided in a
purified (e.g., isolated and substantially pure) form.
35 The polypeptide has enzymatic activity for producing
squalene. That polypeptide is encoded by the
nucleotide sequence which corresponds to, or

-4-

substantially to, that sequence specified by SEQ ID NO:
1. The polypeptide has an amino acid sequence which
corresponds to, or substantially to, the amino acid
sequence specified by SEQ ID NO: 2. Polypeptides
5 having amino acid sequences which correspond
substantially to that encoded by the specified nucleic
acid sequence have different amino acid sequences
(e.g., a minor number of amino acids of the sequence
can be deleted, added or substituted), but the same
10 type of biological activities as that encoded by the
specified sequence, although those biological
activities may differ in degree.

In another aspect, the present invention
relates to fragments of polypeptides (e.g., polypeptide
15 derivatives) encoded by nucleotide sequences which
correspond to, or substantially to, certain nucleotide
subsequences contained within that sequence specified
by SEQ. ID NO: 1. Such fragments represent domains of
the full length (i.e., intact) polypeptides. Such
20 fragments can be, for example, transit peptides useful
for directing polypeptides to subcellular compartments,
or polypeptide domains having properties such as
catalytic activity, substrate binding activity, or the
like.

25 The nucleotide sequence of the present
invention can be incorporated (i.e., in an operative
fashion) into heterologous systems (e.g., yeast,
bacteria or certain plants) in order that the
respective polypeptide can be synthesized thereby. The
30 nucleotide sequence can be incorporated into plants
(e.g., rice, corn, tobacco or tomato) using
transformation techniques or viral gene expression
systems. The RNA molecules or polypeptides encoded by
those nucleotide sequences can be used to alter the
35 biosynthetic pathway of (i) sterols (e.g.,
cycloartenol, cholesterol, obtusifoliol, and related
compounds), or (ii) other isoprenoids (e.g., squalene,

phytoene, lycopene, beta-carotene, and related compounds). For example, the nucleotide sequence can be incorporated into a heterologous system in order to effect the accumulation in that system of various isoprenoids, including squalene. Alternatively, the polypeptides can be isolated in order to be used as enzymes in the in vitro synthesis of sterols or isoprenoids.

In another aspect, the present invention relates to recombinant DNA or RNA molecules. Such molecules include DNA sequences, corresponding RNA sequences, or subsequences of such DNA and RNA sequences. Certain sequences and subsequences (e.g., promoters, enhancers, terminators and replication signals) are capable of facilitating the expression of squalene synthetase. A DNA sequence or at least one subsequence has a nucleotide sequence which is specified, or substantially specified, by at least a portion of that nucleotide sequence specified by SEQ ID NO: 1. The DNA sequence is isolated from a Nicotiana species, such as Nicotiana benthamiana.

The recombinant molecule can be considered a plasmid or a vector. The recombinant molecule can be a plasmid or vector tailored for transfer of the recombinant molecule to plant or other cells. Recombinant molecules also can be contained in a transgenic plant cell, such as a tobacco plant cell.

In another aspect, the invention relates to the delivery and expression of sequences or subsequences as described by SEQ ID NO: 1 via transient virus-based gene delivery systems. Such a system is described in European Patent Application No. 406,267 and U.S. Patent No. 5,316,931, which are incorporated herein by reference. Such a system involves delivery of a selected nucleotide sequence as part of, or in conjunction with, a self-replicating DNA or RNA molecule (i.e., a virus), such that the exogenous gene

-6-

is replicated and expressed during the course of replication and expression of viral or virus-based nucleic acids and proteins. Such gene delivery systems may be used for expression of nucleic acid sequences or subsequences as described by SEQ ID NO: 1 in either sense orientation for the expression of polypeptides, or in antisense orientation for the delivery of RNA molecules capable of inhibiting expression of the target gene or other homologous genes. Genes or gene sequences delivered in such a manner are considered to be functionally inserted in the target organism such as a tobacco plant.

A further aspect of the present invention is a crop composed of a plurality of plants having the nucleotide sequence of the present invention, or a subsequence thereof, functionally inserted therein; and planted together in an agricultural field, including a greenhouse or growth chamber.

Compositions including genetic sequences and subsequences encoding enzymes for expression in plants, such as tobacco plants, impart those plants with the ability to produce altered levels of sterols and/or isoprenoids. As such, there is provided a method for altering the synthesis of sterols and isoprenoids in plants, which method involves inserting a recombinant genetic construct into plant cells. Such a construct can provide for synthesis of naturally occurring sterols (e.g., cycloartenol, obtusifoliol or cholesterol) and other isoprenoids (e.g., squalene, phytoene or beta-carotene) within such plant cells. For example, certain recombinant genetic constructs of the present invention are capable of increasing or decreasing expression of at least one naturally occurring enzyme in order that resulting transformed plants exhibit enhanced ability to produce a sterol or a carotenoid. As such, there is provided a method for

- 7 -

altering the biosynthetic pathway of various components in plants.

In yet another aspect, the present invention relates to an antisense sequence for that sequence which corresponds to, or substantially to, the totality or a subset of that nucleic acid sequence specified by SEQ ID NO: 1. As such, that sequence encodes RNA molecules capable of inhibiting expression of the corresponding gene and genes related thereto. Antisense RNA is capable of reducing the expression of genes within plant cells. See, Ecker et al., Proc. Nat. Acad. Sci. USA, Vol. 83, p. 5372, (1986) and Rothstein et al., Proc. Nat. Acad. Sci. USA, Vol. 84, p. 8439 (1987). The nucleotide sequence can be incorporated into plants (e.g., tobacco or tomato) using transformation techniques or viral gene expression systems. As a result, the present invention provides for a method for altering the synthetic pathway of sterols and isoprenoids. For example, the expression of an antisense molecule can be useful for suppressing or preventing synthesis of sterols (e.g., to cause a flux of total carbon available for biosynthesis of carotenoid compounds) or for preventing synthesis of certain isoprenoid compounds. Alternatively, expression of an antisense molecule may be useful in accumulating relatively high levels of certain molecules upstream of a particular metabolic block. Another example is the use of such antisense molecules to deliberately direct metabolites toward one branch of a branched pathway, such as that pathway involved in carotenoid biosynthesis.

Brief Description of the Drawings

Figures 1 and 2 illustrate maps of plasmids pBGC802 and pBGC803, respectively, which each contain the *Nicotiana benthamiana* squalene synthetase gene

- 8 -

cloned in as a PCR fragment into plasmid pCRII
(Invitrogen, San Diego, CA).

Figure 3 illustrates a map of the plasmid
pBGC804 containing the *Nicotiana benthamiana* squalene
5 synthetase gene cloned as an *NdeI/SalI* fragment into
the expression vector pT7-7.

Figure 4 illustrates a map of the
transcription plasmid pBGC805 containing a 638 bp
antisense fragment of *Nicotiana benthamiana* squalene
10 synthetase cloned into the *XhoI* and *AvrII* sites of the
RNA viral vector TTO1A.

Detailed Description of the Preferred Embodiments

The nucleotide sequences of genetic materials
15 of the present invention are isolated from a plant, and
preferably from a *Nicotiana* species. A plant is an
organism belonging to the kingdom Plantae. See, Raven,
et al., p. 178 (1981). Most preferably, the nucleotide
sequences are isolated from *Nicotiana benthamiana*.

20 Examples of other *Nicotiana* species include *Nicotiana*
debneyi, *Nicotiana glauca*, *Nicotiana glutinosa*,
Nicotiana rustica, *Nicotiana svaveolens* and *Nicotiana*
tabacum. Examples of cultivars of *Nicotiana tabacum*
include flue-cured tobacco (e.g., NK 326), Burley
25 tobacco (e.g., KY 14) and Maryland tobacco (e.g., MD
609).

The nucleotide sequence of isolated genetic
material of the present invention can be obtained by a
variety of techniques. The sequence can be obtained by
30 sequencing non-vector nucleotide sequences of
recombinant molecules. Nucleotide sequence information
can be obtained by employing widely used DNA sequencing
protocols. Examples of suitable nucleotide sequencing
protocols can be found in Berger and Kimmel, Methods in
35 Enzymology Vol. 51, Guide to Molecular Cloning
Techniques, Academic Press (1987). Nucleotide
sequence information from several recombinant DNA

-9-

isolates, including isolates from both cDNA and genomic libraries, can be combined so as to provide the entire amino acid coding sequence, as well as the nucleotide sequences of upstream and downstream nucleotide sequences.

For gene isolation, mRNA is converted into cDNA, and the resulting cDNA is cloned. The cloned cDNA then can be used directly, or it, or sequences derived from it, can be utilized for acquiring the entire gene, either (i) from a library (e.g., in a lambda or plasmid vector) using sequence information to screen the library and detect the desired clone, or (ii) by amplification with PCR (polymerase chain reaction) and subsequent cloning into a suitable vector. For example, the 5' and 3' RACE (Rapid Amplification of cDNA Ends) reactions can be used to clone overlapping 5' and 3' ends of the gene of interest with subsequent assembly of the complete gene.

Nucleotide sequences obtained from sequencing specific genetic library isolates can be subjected to further analysis in order to identify regions of interest in the genetic material. These regions of interest include additional open reading frames, promoter sequences, termination sequences, and the like.

Isolated DNA can be characterized as being selected from the group consisting of:

(a) Isolated DNA consisting of DNA having the nucleotide sequence which corresponds to, or substantially to, SEQ ID NO: 1.

(b) Isolated DNA which hybridizes to isolated DNA of (a) above which encodes an enzyme or fragment thereof having squalene biosynthetic activity.

Hybridization of such sequences may, for example, be carried out under stringent conditions (e.g., conditions represented by a wash stringency of 0.1x SSC

-10-

(1x SSC is 0.3M NaCl, 0.03M sodium citrate), 0.1% SDS at 60°C to DNA of (a) above) in a standard in situ hybridization assay. See J. Sambrook et al., Molecular Cloning: A Laboratory Manual (2d Ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989). In general, such sequences will be at least 95% homologous, often at least 98% homologous, and even at least 99% homologous with the sequences of (a) above.

(c) Isolated DNA homologous to isolated DNA of (a) and (b) above. Homology relates to substantial or complete identity of nucleic acid sequences. Two nucleic acid fragments are homologous if they are capable of hybridizing to one another under hybridization conditions described in Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., pp. 324-325 (1982). Homologous sequences can be identified that contain less than about 5% base pair mismatches by using the following wash conditions: 2 x SSC, 0.1% SDS, room temperature twice, 30 minutes each; then 2 x SSC, room temperature twice, 10 minutes each. Homology can be assessed using computer programs such as DNASIS™ and PCGene (LKB, Hitachi Corporation, Japan, and Intelligenetics, Palo Alto, CA.) whereby the degree of homology is within the limits of homology considered significant by Bost et al., Biochem. Biophys. Res. Commun., Vol. 128, pp. 1373-1380 (1985). More preferably, homologous nucleic acid strands contain less than 2% base pair mismatches, even more preferably less than 1% base pair mismatches. These degrees of homology can be selected by using more stringent wash conditions for identification of clones from gene libraries (or other sources of genetic material), as is well known in the art.

(d) Isolated DNA differing from the isolated DNA of (a), (b) and (c) above in nucleotide sequence due to the degeneracy of the genetic code, and which

-11-

encodes either (i) a polypeptide identical to the polypeptide specified by SEQ ID NO: 2, or (ii) an enzyme or fragment thereof having sterol or isoprenoid biosynthetic activity.

5 There is about 43 to about 49 percent conservation between the nucleotide coding region specified by SEQ ID NO: 1 and those squalene synthetase genes set forth in Jennings, et al., Proc. Nat. Acad. Sci. USA, Vol. 88, p. 6038 (1991), McKenzie, et al., J. Biol. Chem., Vol. 267, p. 21368 (1992) and Robinson, et al., Mol. Cell. Biol., Vol. 13, p. 2706 (1993); as
10 determined by PC/GENE Multiple Sequence Alignment program (IntelliGenetics, Inc., Mountain View, CA). With regards to the polypeptide encoded by the nucleic
15 acid sequence specified by SEQ ID NO: 1, there is a 21.8 percent identity and 24.6 percent similarity between the amino acid sequence specified by SEQ ID NO:
20 2 and the squalene synthetase sequences set forth in Jennings, et al., Proc. Nat. Acad. Sci. USA, Vol. 88, p. 6038 (1991), McKenzie, et al., J. Biol. Chem., Vol. 267, p. 21368 (1992) and Robinson, et al., Mol. Cell. Biol., Vol. 13, p. 2706 (1993). However, there is 90 percent homology between the conserved residues found
25 in known squalene synthetase amino acid sequences and those regions of homology found in the amino acid sequence specified by SEQ ID NO: 2. For the sequence specified by SEQ ID NO: 2, the conserved regions of amino acids are in positons 1, 40, 44, 48-52, 54, 55, 58, 63, 66, 69-71, 73, 74, 77, 78, 80-82, 90, 94, 97,
30 106, 108, 116, 122, 132, 136, 140, 147, 148, 150-152, 168-177, 179, 180, 200-214, 216, 217, 225, 227-229, 231, 233, 236, 248, 255, 262-264, 266, 267, 269, 271-273, 283, 285-294, 296-298, 303, 306, 311, 312, 314, 316, 350, 351.

35 The nucleotide sequences of the present invention are capable of encoding polypeptides having enzymatic activity for sterol biosynthesis and

-12-

isoprenoid biosynthesis. Such polypeptides have domains of amino acid sequences having catalytic activity. The catalytic domains demonstrate enzymatic activity, can be isolated, and can be expressed in in vivo or in vitro systems.

A polypeptide derivative of a particular biosynthetic enzyme can differ in length from the natural enzyme, but typically contains numerous amino acids from the natural enzyme in the same primary order as found in that enzyme as obtained from a natural source. Such a polypeptide molecule has substantially the same full length amino acid sequence as the natural enzyme but possesses minor amino acid substitutions that do not substantially affect the ability of that derivative to cause biosynthesis of sterols or isoprenoids. Derivatives include glycosylated forms, aggregative conjugates with other enzyme molecules and covalent conjugates with unrelated chemical moieties. Covalent derivatives are prepared by linkage of functionalities to groups which are found in the enzyme amino acid chain or at the N- or C-terminal residue by means known in the art.

Isolated nucleotide sequences encoding biosynthetic enzyme can be used to produce purified enzyme or derivatives thereof by either recombinant DNA methodology or by in vitro polypeptide synthesis techniques. Purified and isolated polypeptide or nucleotide sequences are present in the substantial absence of other biological macromolecules of the same type. Purified genes and polypeptides of the present invention typically have at least 95% by weight, more preferably at least 99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present; but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000, can be present.

-13-

Biosynthetic enzymes and polypeptide derivatives of those enzymes can be expressed by recombinant techniques when a DNA sequence encoding the relevant molecule is functionally inserted into a vector (e.g., in proper reading frame and orientation, as is well understood by those skilled in the art). Typically, the relevant gene will be inserted downstream from a promoter and will be followed by a stop codon, although production as a hybrid protein followed by cleavage may be used, if desired. In general, host-cell-specific sequences improving the production yield of enzyme and enzyme derivatives can be used, and appropriate control sequences (e.g., enhancer sequences, polyadenylation sequences, and ribosome binding sites) can be added to the expression vector.

A genetic construct can be prepared and used to transform plant cells. The transformed plant cells may be cells in culture, may be present as a disorganized mass in callus, leaf explants, or shoot cultures, or may be a post-transformation differentiated plant or plant part, such as seeds, leaves, roots, or the like. The foreign construct normally is present in all or substantially all of the cells of the plant tissue, but expression may be limited to particular cells or particular times in the development of the plant. The foreign construct normally includes transcriptional and translational initiation and termination signals, with the initiation signals 5' to the gene of interest and the termination signals 3' to the gene of interest.

The transcriptional initiation region which includes an RNA polymerase binding site (i.e., promoter) may be native to the host or may be derived from an alternative source, where the region is functional in the plant host.

-14-

The transcriptional initiation regions may include, in addition to the RNA polymerase binding site, regions providing for regulation of transcription. The 3' termination region may be derived from the same gene as the transcriptional initiation region or from a different gene. For example, where the gene of interest has a transcriptional termination region functional in the host species, that region may be retained with the gene.

An exemplary expression cassette can be constructed to include a) a transcriptional initiation region, b) the biosynthetic enzyme gene under the transcriptional regulational control of the transcriptional initiation region, c) the translational initiation codon, d) the coding sequence of the gene, with or without introns, and e) the translational stop codons, followed by f) the transcriptional termination region. The transcriptional termination region includes the terminator, and may include a polyadenylation signal sequence, and other sequences associated with transcriptional termination. The direction is 5'-3' in the direction of transcription.

When the expression product of the gene is to be located in a subcellular or extracellular compartment other than the cytoplasm, the gene usually is constructed to include particular amino acid sequences which result in translocation of the product to a particular site. That site may be an organelle, such as the chloroplast, mitochondrion, endoplasmic reticulum or nucleus, the cell plasma membrane, or may be secreted into the periplasmic space or into the external environment of the cell. Various secretory leaders, membrane integrator sequences, and translocation sequences for directing the peptide expression product to a particular site are described in the literature. See, for example, Cashmore et al.,

-15-

Biotechnology, Vol. 3, pp. 803-808 (1985), and Wickner and Lodish, Science, Vol. 230, pp. 400-407 (1985).

The expression cassette normally is carried on a vector having at least one replication system. For convenience, it is common to have a replication system function in E. coli such as ColE1, pSC101, pA-CYC184, or the like. In this manner, at each stage after each manipulation, the resulting construct may be cloned, sequenced, and the correctness of the manipulation determined.

In addition to the replication system, there frequently is at least one marker present, which may be useful in one or more hosts, or different markers for individual hosts. That is, one marker may be employed for selection in a prokaryotic host, while another marker may be employed for selection in a eukaryotic host, particularly the plant species host. The markers may be protection against a biocide, such as antibiotics, toxins, heavy metals, or the like; or complementation, imparting prototrophy to an auxotrophic host.

The various fragments comprising the various constructs, expression cassettes, markers, and the like may be introduced consecutively by restriction enzyme cleavage of an appropriate replication system, and insertion of the particular construct or fragment into the available sites. After ligation and cloning, the vector may be isolated for further manipulation. All of these techniques are amply exemplified in the literature and find particular exemplification in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1982).

Once the vector is completed, the vector may be introduced into plant cells. Techniques for transforming plant cells include microinjection, particle bombardment, direct DNA uptake, such as using

-16-

polyethylene glycol, electroporation, viral infection, and transformation with Agrobacterium. For representative techniques, see, D'Halluin et al., The Plant Cell, Vol. 4, p. 1495 (1992); Tomes et al., Plant Mol. Biol., Vol. 14, p. 261 (1990); and Zhu et al., Plant Cell, Tissue and Organ Culture, Vol. 22, p. 145 (1991).

The nucleotide sequence encoding a given enzyme can be functionally inserted into plants or transiently expressed by virus-based gene delivery systems. Such a system is described in European Patent Application Nos. 67,553, 194,809 and 406,267, PCT WO 93/20217 and U.S. Patent Nos. 5,304,731 and 5,316,931; which are incorporated herein by reference. Such a system involves delivery of a selected nucleotide sequence as part of, or in conjunction with, a self-replicating DNA or RNA molecule (e.g., a virus), such that the exogenous gene is replicated and expressed during the course of replication and expression of viral or virus-based nucleic acids and proteins. Such gene delivery systems, in addition to enhancing gene "copy number" through the replicative potential of the given virus or virus-based nucleic acids, facilitate the timed delivery of such exogenous genes at the desired state of host development.

An exemplary virus-based gene delivery system employs tobacco mosaic virus. A DNA copy of the virus has a DNA sequence of the present invention inserted therein using conventional techniques of molecular cloning. The cloned DNA copy of the resulting viral vector then is transcribed to produce an RNA. The resulting RNA transcript vector then can be used to inoculate a grown *Nicotiana benthamiana* or *Nicotiana tabacum* plant by applying that RNA transcript onto a carborundum-dusted leaf in the direction of the leaf tip with a gloved finger. The plant so inoculated and infected with the virus vector is allowed to continue

-17-

growing for about 3 weeks and then is harvested. The harvested plant can be extracted immediately or frozen for storage purposes. This infected plant material, or the vector virions isolated from it, can then be used for the inoculation of a multiplicity of plants for purposes of significantly amplifying the delivered gene or gene product. In order to accomplish this, the leaf tissue so collected is mixed with a 10mM phosphate buffer (pH 7.5) at a ratio of about 1:10 (w/v). The mixture is macerated using a high speed blender, and centrifuged so as to obtain a liquid inoculum. The inoculum then can be applied to a growing plant, such as a tobacco plant, by applying the inoculum to injured (e.g., lacerated) regions of that plant. For example, the upper most leaves of the growing plant can be cut using an inoculum-wetted cutting blade (e.g., by spray nozzles located in the cutting blade); or the inoculum can be sprayed onto a specific region of one leaf of the plant as a high pressure spray. The plant is allowed to continue growing in order that the viral vector can systemically infect the plant. At a desired stage of infection, the plant is harvested.

The following examples are provided in order to further illustrate the invention but should not be construed as limiting the scope thereof. Unless otherwise noted, all parts and percentages are by weight.

Example 1

Isolation of a gene encoding squalene synthetase was carried out as follows:

A. Isolation of RNA from Nicotiana benthamiana :

About 100 mg of plant leaf tissue was harvested, transferred to a 1.5 ml microfuge tube, frozen with liquid nitrogen, and homogenized in one ml of AGRIsol (Biogentex, Houston, TX) using a teflon

-18-

pestle connected to a Moto Tool™ (Dremel Corp.,
Racine, WI). Immediately following homogenization, 100
μl of chloroform was introduced into the tube. The
mixture was shaken by hand for 20 sec. Then, the
5 mixture was incubated for 5 min. on ice, and
centrifuged for 10 min. at 10,000 x g at 4°C. The
aqueous phase of the centrifuged mixture was
transferred to a separate tube, and the RNA was
precipitated from that phase by addition of one volume
10 of isopropanol. After incubation on ice for 5 min.
that sample was centrifuged for 10 min. at 10,000 x g
at 4°C. The resulting pellet was collected and washed
twice with ethanol (75% in water). The pellet was
air-dried for about 15 min. The pellet was resuspended
15 in 20 μl RNase-free dH₂O. The RNA concentration was
calculated by determining the OD₂₆₀ nm (1 OD₂₆₀ nm = 40
μg/ml).

B. Isolation of an internal cDNA fragment of
squalene synthetase.

20 The literature was examined for nucleotide or
amino acid sequences from human and yeast encoding the
gene for squalene synthetase. Regions of conserved
amino acid sequence were used to design suitable
degenerate oligonucleotide primers. See Robinson *et*
25 *al.*, Molecular and Cellular Biology, Vol. 13, p. 2706
(May 1993). Primers were synthesized from these
sequences on an Applied Biosystems Model 391 PCR Mate,
or were obtained from commercial sources.

Approximately 150 ng of total RNA was mixed
30 with 10 pg of primer SSP-1, (5'-GGC TCG AGA TIG CCA TIA
CYT GNG GNA TNG CXC AXA A-3', where X is G or A, Y is C
or T, N is G, A, C, or T, and I is inosine) and dried
in a lyophilizer. Five microliters of a 2.5 mM dNTP
mix (dATP, dCTP, dGTP, and dTTP) was added to the dried
35 RNA-primer pellet, heated 5 min at 70°C, and cooled to
37°C. The reaction mixture was made up to 10 μl with
final concentrations of 50 mM Tris-HCl, pH 8.3, 50 mM

-19-

KCl, 5 mM MgCl₂, 0.5 mM spermidine, and 10 mM DTT. Five units of avian myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison, WI) were added and the reaction was incubated for 2 hr at 37°C.

5 Following first strand cDNA synthesis, 10 pg of primer SSP-2, (5'-GGC TCG AGT AYT GYC AYT AYG TIG CNG GIC TNG TNG G-3'), where X is G or A, Y is C or T, N is G, A, C, or T, and I is inosine), was added along with 5 µl of GeneAmp® 10X PCR buffer (500 mM KCl, 100
10 mM Tris, pH 8.3, 15 mM MgCl₂, and 0.01% (w/v) gelatin) (Perkin-Elmer Cetus, Norwalk, CT), 30 µl distilled, deionized water, and 5 units AmpliTaq® DNA polymerase (Perkin-Elmer Cetus). PCR amplification was performed using a DNA Thermal Cycler (Perkin-Elmer Cetus) with 1
15 cycle at 95°C for 5 min, 35 cycles of 50°C for 2 min, 72°C for 2 min, and 95°C for 2 min, and 1 cycle of 72°C for 9 min. The amplified products were re-amplified in a 50 µl reaction volume with final concentrations of 50 mM KCl, 20 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 0.01%
20 (w/v) gelatin, 0.5 mM each of dATP, dGTP, dCTP, dTTP, and 5 units AmpliTaq® DNA polymerase. The re-amplified products were analyzed by separation on a 1% SeaKem® agarose (FMC BioProducts, Rockland, ME) gel in TAE (1x TAE Buffer is 40 mM Tris-Acetate, 2 mM EDTA) by gel
25 electrophoresis, and a band corresponding to the predicted size of 400 bp was excised and the DNA purified from the gel fragment using Geneclean™ (Bio 101, LaJolla, CA).

30 The isolated 400 bp PCR fragment was cloned into plasmid pCRII (Invitrogen Corporation, San Diego, CA). Clones containing the 400 bp insert were subjected to DNA sequence analysis using the Sequenase® Version 2.0 DNA Sequencing Kit (United States Biochemical Corporation, Cleveland, OH). A representative clone,
35 designated pSS400, was used for subsequent analysis and manipulation.

-20-

DNA sequence was determined by separation of the fragments on a polyacrylamide/urea gel (BioRad, Richmond, CA), drying the gel on a sheet of Whatman 3MM paper (Whatman International Ltd., Maidstone England) using a BioRad Model 583 gel dryer. The dried gel was exposed to X-ray film, and the DNA sequence was read. The sequence was examined for homology with the published squalene synthetase sequences. The deduced amino acid sequence encoded by the Nicotiana benthamiana squalene synthetase cDNA fragment was found to be 92% homologous to the conserved regions of amino acid sequence reported. See Robinson et al., Molecular and Cellular Biology, Vol. 13, p. 2706 (May 1993). All non-identical amino acids in these regions were conserved substitutions.

C. 3' RACE amplification of squalene synthetase.

Sequence data generated from the 400 bp internal squalene synthetase cDNA fragment were used to design additional primers to facilitate the isolation of the complete cDNA. These were synthesized on an Applied Biosystems Model 391 PCR Mate, or were obtained from commercial sources.

Approximately 150 ng of total RNA was heated with 10 pg of Adapter Primer (Gibco BRL, 5'-GGC CAC GCG TCG ACT AGT AC(T)₁₇-3') for 10 min. at 65°C and then chilled 2 min on ice. The reaction mixture was made up to 20 µl total volume with final concentrations of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl₂, 100 µg/ml BSA, 10 mM DTT, 500 nM Adapter Primer and 0.5 mM each dATP, dCTP, dGTP and dTTP. The mixture was equilibrated 2 min at 42°C. 200 units of SuperScript™ reverse transcriptase were added and the mixture incubated 30 min. at 42°C. Two units of E. coli RNase H was added and the mixture incubated 10 min at 42°C to yield the first strand cDNA.

-21-

The first strand cDNA was directly amplified by the PCR method. A 50 μ l reaction was assembled with a final composition of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM , 100 μ g/ml BSA, 200 nM primer SSP-3 (5'-TCC ATG GGT TTA TTT CTT CAG -3') 200 nM Universal Amplification Primer (Gibco BRL, 5'-CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT AC -3'), 0.2 mM each dATP, dCTP, dGTP and dTTP, and 5 units AmpliTaq[®] DNA Polymerase (Perkin-Elmer Cetus). Amplification was in a DNA Thermal Cycler with 1 cycle of 5 min. at 94°C, 35 cycles of 2 min at 94°C, 2 min at 55°C, 2 min at 72°C, and 1 cycle of 5 min. at 72°C. An aliquot of the amplified PCR products was used directly in a nested amplification performed in a 50 μ l reaction with a final composition of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM , 0.001% (w/v) gelatin, 0.2 mM each dATP, dCTP, dGTP and dTTP, 200 nM Universal Amplification Primer, 200 nM primer SSP-4 (5'-CAA TGT CTA AAT GAC ATG GTC ACT AAT GC- 3'), 1 μ l PCR products, and 2.5 units AmpliTaq[®] DNA Polymerase. Amplification was performed in a DNA Thermal Cycler with 1 cycle of 5 min. at 94°C, 35 cycles of 2 min at 94°C, 2 min at 55°C, 2 min at 72°C, and 1 cycle of 5 min. at 72°C.

D. Southern Analysis of PCR Products:

Nested PCR 3' RACE products were analyzed by separation on a 1% SeaKem[®] agarose (FMC BioProducts, Rockland, ME) gel in TAE buffer. The PCR products in the gel were denatured by treatment for 20 min. in 1.5 M NaCl, 0.5 N NaOH and neutralized by soaking in several volumes of 1.5 M NaCl, 1 M Tris-HCl (pH 8.0). The PCR products were transferred to a Flash[®] nylon membrane (Stratagene Cloning Systems, La Jolla, CA) using a PosiBlot[®] pressure blotter (Stratagene) and were UV-crosslinked to the membrane using a Stratalinker[®] 2400.

Hybridization and detection of squalene synthetase homologous sequences were performed using

-22-

the chemiluminescent Genius® system (Boehringer Mannheim Biochemicals, Indianapolis, IN). The membrane was prehybridized for 1 hr. at 60°C in 10 ml hybridization solution (5X SSC, 1X Blocking solution, 0.1% N-laurylsarcosinate, 0.02% sodium dodecylsulfate (SDS); 10X Blocking solution is 10%(w/v) Blocking Reagent (Boehringer Mannheim Biochemicals, Indianapolis, IN) in 100 mM maleic acid at pH 7.5, 150 mM NaCl). Incubations were in a Model 1040-01-0 rotating bottle hybridization incubator (Robbins Scientific, Sunnyvale, CA). Heat-denatured (5 min. at 100°C) probe was added to the prehybridization mixture at a final concentration of 1.25 ng/ml, and incubation of the resulting mixture was continued 4-16 hr. at 60°C. The membrane was washed twice for 5 min. in 2X SSC, 0.1% SDS at room temperature, and twice for 15 min. in 0.1X SSC, 0.1% SDS at 60°C. For chemiluminescent detection, the membrane was rinsed in 100 mM maleic acid, 150 mM NaCl, and incubated for 30 min. at room temperature in 1X Blocking solution. Alkaline phosphatase-conjugated anti-digoxigenin Fab fragments were added (1:10,000 dilution), and incubation was continued for 30 min. at room temperature. The membrane was washed twice for 15 min. in 100 mM maleic acid, 150 mM NaCl, at room temperature. The membrane was equilibrated for 2 min. in 100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 50 mM MgCl₂. The membrane was placed on a sheet of clear acetate film and Lumi-Phos® 530 (Boehringer Mannheim Biochemicals, Indianapolis, IN) was added on the DNA side of the membrane. Another sheet of acetate film was used to cover the membrane, and the membrane was exposed to X-ray film. Positive signals on the X-ray film indicated the presence of PCR products containing squalene synthetase homologous sequence.

Chemiluminescent probe for the hybridization procedure was generated by labeling the 400 bp insert

-23-

sequences of plasmid pSS400. One μg of plasmid pSS400 was digested with EcoRI to excise the insert. The squalene synthetase cDNA fragment was separated on an agarose gel and excised after visualization by ethidium bromide staining. The DNA was purified from the gel fragment using Geneclean™ and resuspended in 14 μl dH_2O . The DNA was heat-denatured 10 min at 100°C and chilled on ice. The Genius® Kit 2 (Boehringer Mannheim Biochemicals) was used to label the fragment with digoxigenin-dUTP according to the manufacturer's protocols. The probe concentration was determined by comparison with a dilution series of a known standard on a Flash® membrane, detected by chemiluminescence as above.

15 E. Cloning of the 3' RACE products.

The nested PCR 3' RACE products of squalene synthetase were cloned using the pCRII vector. Clones were screened by digestion with EcoRI to liberate the insert, separation on an agarose gel, transfer to a nylon membrane, and hybridization and detection as described above. Clones exhibiting a positive hybridization signal were subjected to DNA sequence analysis as described above. The sequence was examined for homology with the published squalene synthetase sequences. Clones were identified that exhibited at least 90% homology to the conserved regions in other squalene synthetase genes.

25 F. 5' RACE amplification and cloning of squalene synthetase.

30 The 5' RACE procedure (Frohman et al., Proc. Nat. Acad. Sci. USA, Vol. 85, pp. 8998-9002 (1988)) was used to amplify the 5' terminus of squalene synthetase mRNA.

35 Four to six μg total Nicotiana benthamiana RNA was combined with 10 pmole of primer SSP-5 (5'-GTA AGT CAA ACA ATC TTC TAC ATG TGA-3') and the mix was heated for 10 min at 70°C and chilled on ice. The

-24-

reaction was brought to a volume of 20 μ l in 20 mM Tris-HCl (pH 8.4, 50 mM KCl, 2.5 mM MgCl₂, 0.1 mg/ml BSA, 10 mM DTT, 0.2 mM each dATP, dCTP, dGTP and dTTP, and 200 units reverse transcriptase. The mixture was
5 incubated for 10 min at room temperature and 50 min at 42°C. The reaction was stopped by heating for 5 min at 90°C and chilled on ice. Two units *E. coli* RNase H were added and the reaction incubated 20 min at 37°C. The single-stranded cDNA was purified from the previous
10 reaction using Geneclean™, resuspended in 16 μ l dH₂O, heated 10 min at 70°C and chilled on ice. The tailing reaction was initiated by adding 1 μ l of 10X reaction buffer (200 mM Tris-HCl, (pH 8.4), 500 mM KCl, 25 mM MgCl₂, 1 mg/ml BSA), 2 μ l 2 mM CTP, and 15 units of
15 terminal transferase (TdT) to the single-stranded cDNA. After 10 min at 37°C, the TdT was inactivated for 10 min at 70°C and the reaction chilled on ice.

Ten μ l of the dC-tailed cDNA was used in the amplification step. The volume of the reaction was
20 brought to 100 μ l by the addition of 76.5 μ l dH₂O, 9.5 μ l 10X reaction buffer, 0.2 mM each dATP, dCTP, dGTP and dTTP, 10 pmole primer SSP-6 (5'-CTG AAG AAA TAA ACC CAT GGA -3'), 10 pmole Anchor primer (Gibco BRL, 5'-CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT ACG GGI IGG GII GGG
25 IIG-3') and 5 units *Taq* DNA polymerase (Gibco BRL). The amplification was performed with one cycle of 2 min at 94°C, 37 cycles of 30 sec at 94°C, 15 sec at 55°C, 40 sec at 72°C, and one cycle at 72°C for 5 min. The amplification products were analyzed by agarose gel
30 electrophoresis and a DNA fragment of approximately 800 bp was visualized after ethidium bromide staining.

One microliter of the first reaction was amplified by PCR using the Universal Amplification Primer (UAP) (Gibco BRL, 5'- CUA CUA CUA CUA GGC CAC
35 GCG TCG ACT AGT AC -3'). The reaction was composed of 80.5 μ l dH₂O, 10 μ l 10X *Taq* polymerase buffer (Gibco BRL), 5 μ l 50 mM MgCl₂, 1 μ l of the DNA Polymerization

-25-

Mix (Pharmacia LKB Biotechnology, Piscataway, NJ), 1 μ l of the first amplification reaction, and 2.5 units Taq polymerase. The amplification was performed with one cycle of 2 min at 94°C, 30 cycles of 40 sec at 94°C, 30 sec at 55°C, 1 min at 72°C, and one cycle at 72°C for 5 min. The amplified products were purified using a Magic PCR Prep[®] column (Promega, Madison, WI) as recommended by the manufacturer followed by agarose gel electrophoresis. The resulting 800 bpDNA fragment was excised from the agarose and purified using Geneclean[™]. The fragment was cloned into a pCRII vector using standard cloning techniques. The clones were subjected to DNA sequence analysis using the Sequenase Version 2.0 DNA Sequencing Kit (United States Biochemical Corporation, Cleveland, OH). The sequence was examined for homology with the published squalene synthetase sequences. Clones were detected that exhibited at least 90% homology to the conserved regions in other squalene synthetase genes.

20 G. Cloning of Squalene Synthetase.

A region of the squalene synthetase encompassing the start codon and the stop codon was amplified using the PCR as follows: Total RNA from 500 mg of fresh leaves of *Nicotiana benthamiana* was extracted with Trizol[™] RNA extraction kit (Gibco BRL). The first DNA strand was synthesized by a reverse transcription reaction using 6 μ g of total RNA as a template, oligo(dT)₁₂₋₁₈ as primer (0.5 μ g), and the SuperScript[™] preamplification kit (Gibco BRL). The RNA-primer mix was brought to a total volume of 14 μ l, heated for 10 min at 70°C, then chilled on ice. The reaction volume was adjusted to 20 μ l by adding 2 μ l of 10X synthesis buffer (200 mM Tris-HCl (pH 8.4), 500 mM KCl, 25 mM MgCl₂, 1 mg/ml BSA), 2 μ l of 0.1 M DTT, 1 μ l of 10 mM dNTP mix and 1 μ l (200 units) of reverse transcriptase. The mixture was incubated for 10 min at room temperature and 50 min at 42°C. The reaction was

-26-

stopped by heating 5 min at 90°C and chilled on ice. Then, 1 µl of *E. coli* RNase H (two units) was added and the mixture incubated 20 min at 37°C.

For the polymerase chain reaction (PCR) step, two primers (10 pmole of each) were added (SSP-7 (5'-CAA CGC TTT CTC CTC TTA CCA -3') and SSP-8 (5'-CGT CTA AGA TCG GTT TCC GGA -3')) and the reaction mix volume increased to 100 µl with 8 µl of 10 X synthesis buffer, 0.5 µl of *Taq* DNA polymerase and water. PCR was performed using 94°C for 40 sec, 55°C for 20 sec and 72°C for 1 min for 35 cycles, and 94°C for 40 sec, 55°C for 20 sec and 72°C for 6 min for one cycle.

The PCR products were analyzed by agarose gel electrophoresis. A DNA fragment of the expected size of 1275 bp was excised from the agarose gel, and purified using Geneclean™. The PCR product was then ligated to the pCR II using the manufacturer's recommendations. Following transformation, fourteen colonies were analyzed by plasmid DNA isolation and digestion with *Eco* RI. Plasmid DNA from three independant clones containing the expected 1275 bp insert were purified using the Wizard midiprep purification kit (Promega Corp.) and the sequences determined. A single example (designated pBGC802, Figure 1) was chosen and used as a template for specific amplification of the coding region.

Amplification of the squalene synthetase coding region was carried out as follows: Plasmid pBGC802 (10 ng) was used as a template in amplification by PCR using primers SSP-9 (5'-GCG CAT ATG GGG AGT TTG AGG GCT ATT CT-3') and SSP-10 (5'-CGA GTC GAC TAA GAT CGG TTT CCG GAT AG -3'). Primer SSP-9 was homologous to squalene synthetase gene sequences containing the translational initiation codon. Additionally, several nucleotides were changed to introduce an *Nde* I restriction site in the primer. Primer SSP-10 was complementary to squalene synthetase

-27-

gene sequences containing the translational termination codon with several nucleotides changed to create a *Sal* I restriction site downstream from the stop codon.

The amplification reactions consisted of 80.5 μ l of water, 10 μ l of 10X *Taq* DNA polymerase buffer (Gibco BRL), 5 μ l of $MgCl_2$ 50 mM, 1 μ l (10 pmole) of each primer SSP-9 and SSP-10, 1 μ l of the DNA Polymerization Mix, 1 μ l of the uncut plasmid DNA (pBSG802 at 10 ng/ μ l) and 0.5 μ l (2.5 units) of *Taq* DNA Polymerase (Gibco BRL). The amplifications were performed with 4 min incubation at 94°C; 2 cycles of 40 sec at 94°C, 20 sec at 45°C, 1 min at 72°C; 20 cycles of 40 sec at 94°C, 20 sec at 55°C, 1 min at 72°C; and 5 min incubation at 72°C.

The amplified products were analyzed by agarose gel electrophoresis and the single DNA fragment of 1240 bp was purified using Geneclean®. The PCR products were ligated to the pCR II vector using the directions of the manufacturer. The ligation products were used to transform *E. coli* competent cells (OneShot™ INVαF' competent cells, Invitrogen Corp). Analysis of plasmid DNA from the resulting bacterial colonies revealed an insert of approximately 1245 bp. Plasmid DNA was purified using the Wizard midiprep purification kit and the DNA sequence determined. The resulting clone, designated pBGC803 (Figure 2), thus consisted primarily of the *Nicotiana benthamiana* squalene synthetase coding region.

Cloning of the squalene synthetase gene in a bacterial expression vector was carried out as follows:

Plasmid pBGC803 was cut with *Sal* I and with *Nde* I in order to excise the squalene synthetase coding region. The digestion products were analyzed by agarose gel electrophoresis and the 1240 bp DNA fragment purified using Geneclean™. Plasmid pT7-7 (Tabor et al., Proc. Nat. Acad. Sci. USA, Vol. 82, p. 1074 (1985)) was cut with *Nde* I and *Sal* I and the

-28-

squalene synthetase coding region was inserted followed by transformation of DH10B competent cells (Gibco BRL). One of the resulting clones, designated pBGC804 (Figure 3), contains the *Nde* I/*Sal* I DNA fragment of clone pBGC803.

Competent cells of bacterial strain BL21 (DE3) (Novagen, Inc., Madison, WI) were transformed with plasmid pBGC804. A culture was started from a well isolated colony in media containing 50 µg/mL of ampicillin. When the OD₆₀₀ was approximately equal to 0.4, IPTG was added to a final concentration of 0.4 mM. The culture was maintained at 37°C with agitation. At 0, 10 min, 30 min, 60 min, 90 min, 120 min and 240 min post-induction with IPTG, aliquots of 1.5 mL were taken and the cells pelleted at 14,000 rpm for 3 min. The cell pellet was then resuspended with 100 µl of 1X loading buffer and 10 µl of each aliquot was analyzed for total protein content using a 12% SDS-polyacrylamide precast gel (Novex, San Diego, CA). A protein of approximately 45 kDa increased in intensity from time 0 to time 240 min post-induction with IPTG. The calculated molecular weight for the squalene synthetase protein is 47,073.

Example 2

Insertion of a 700 bp antisense *Nicotiana benthamiana* squalene synthetase sequence into a virus-based gene expression system and expression in transfected plants was accomplished as follows:

A. Insertion of the squalene synthetase gene into an RNA viral vector: RNA viral vector TTOIA was constructed as follows:

An 861 bp fragment from tomato mosaic virus virion RNA (fruit necrotic strain F; ToMV-F) was isolated by RT-PCR using ToMV primers 5'-CTC GCA AAG TTT GGA ACC AAA TCC TC-3' (upstream) and 5'-CGG GGT ACC TGG GCC CCA ACC GGG GGT TCC GGG GG-3' (downstream) and subcloned into the *Hinc*II site of pBluescript KS-

-29-

(Stratagene, LaJolla, CA). A hybrid virus consisting of TMV-U1 and ToMV-F was constructed by swapping an 874 bp *Bam*HI/*Kpn*I ToMV fragment into pBGC152. See, Kumagai et al., Proc. Nat. Acad. Sci. USA, Vol. 89, p. 427

5 (1993), creating plasmid pTTO1. A unique *Avr*II site was inserted downstream of the *Xho*I site in TTO1 by PCR mutagenesis, creating plasmid TTO1A, using the primers 5'-TCC TCG AGC TAG GCT CGC AAA GTT TCG AAC CAA ATC CTC A-3' (upstream) and 5'-CGG GGT ACT GGG CCC CAA CCG GGG
10 GTT CCG GGG G-3' (downstream).

The squalene synthetase 3' RACE product was cloned into plasmid pCRII. Unique *Xho*I and *Avr*II sites were inserted into a 642 bp antisense fragment by PCR mutagenesis. A 50 µl reaction was assembled with a
15 final composition of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl₂, 0.01% (w/v) gelatin, 0.5 mM each of dATP, dCTP, dGTP, and dTTP, 200 nM primer SSP-11 (5'-GCG GCT CGA GGA CTC TAC AAC AC-3'), 200 nM primer SSP-12 (5'-CGG CCT AGG ACA TGT CTG CTT TGC-3'), and 5
20 units AmpliTaq® DNA polymerase. The amplification was performed with one cycle of 2 min at 94°C, 30 cycles of 40 sec at 94°C, 30 sec at 55°C, 1 min at 72°C, and one cycle at 72°C for 5 min. The amplified products were analyzed by separation on a 1% SeaKem® agarose gel in
25 TAE by gel electrophoresis and a band corresponding to the predicted size was excised and the DNA purified using Geneclean™. The isolated antisense squalene synthetase fragment was cloned into the *Xho*I and *Avr*II sites of TTO1A to create plasmid pBGC805 (Figure 4).

30 Plasmid pBGC805, was linearized with *Kpn*I and transcripts were synthesized in vitro using a MEGAscript SP6 Kit and m7G(5')ppp(5')G (Ambion, Austin, TX). *N. icotiana benthamiana* plants were inoculated with in vitro transcripts and maintained in a growth
35 chamber at 25°C and a 12 hr light/dark regime for 13 days. At 6 and 13 days post-inoculation, infected leaves were harvested and analyzed for squalene

-30-

synthetase activity. Isolation of total plant membranes and assay for squalene synthetase enzyme activity were performed as previously described. See Hanley et al., Plant Physiol., Vol. 98, p. 215 (1992).

- 5 By 13 days post-inoculation squalene synthetase activity in the plants transfected with the anti-squalene synthetase construct was undetectable.

-31-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Hanley, Kathleen M.
Nicolas, Olivier
Hellmann, Gary M.
- (ii) TITLE OF INVENTION: DNA Sequence encoding squalene synthetase
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: R. J. Reynolds Tobacco Company
 - (B) STREET: 950 Reynolds Blvd., P. O. Box 1487
 - (C) CITY: Winston-Salem
 - (D) STATE: North Carolina
 - (E) COUNTRY: U. S. A.
 - (F) ZIP: 27102-1487
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Borschke, August J.
 - (B) REGISTRATION NUMBER: 30,539
 - (C) REFERENCE/DOCKET NUMBER: cc-212A
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 910-741-5491
 - (B) TELEFAX: 910-741-5449

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1642 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

-32-

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Nicotiana benthamiana*
 (F) TISSUE TYPE: Leaf

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 112..1344

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATCATCGTTT CCACGCAATT CATCGTTCAA CGACTTCTTC AAATACAACC ATTTTGCCAA	60
CGCTTTCTCC TCTTACCAAA CAAACAACCC CCCACCAAAG GCTGAATAAG A ATG GGG	117
	Met Gly 1
AGT TTG AGG GCT ATT CTG AAG AAT CCA GAG GAT TTA TAT CCA TTG GTG	165
Ser Leu Arg Ala Ile Leu Lys Asn Pro Glu Asp Leu Tyr Pro Leu Val	
	5 10 15
AAG CTG AAG CTA GCG GCT CGA CAC GCG GAG AAG CAG ATC CCG CCG TCT	213
Lys Leu Lys Leu Ala Ala Arg His Ala Glu Lys Gln Ile Pro Pro Ser	
	20 25 30
CCA AAT TGG GGC TTC TGT TAC TCA ATG CTT CAT AAG GTT TCT CGT AGC	261
Pro Asn Trp Gly Phe Cys Tyr Ser Met Leu His Lys Val Ser Arg Ser	
	35 40 45 50
TTT GCT CTC GTC ATT CAA CAA CTT CCA GTC GAG CTT CGT GAC GCC GTG	309
Phe Ala Leu Val Ile Gln Gln Leu Pro Val Glu Leu Arg Asp Ala Val	
	55 60 65
TGC ATT TTC TAT TTG GTT CTT CGA GCA CTT GAC ACT GTT GAG GAT GAT	357
Cys Ile Phe Tyr Leu Val Leu Arg Ala Leu Asp Thr Val Glu Asp Asp	
	70 75 80
ACC AGC ATT CCC ACC GAT GTT AAA GTT CCT ATT CTG ATC TCT TTT CAT	405
Thr Ser Ile Pro Thr Asp Val Lys Val Pro Ile Leu Ile Ser Phe His	
	85 90 95
CAG CAT GTT TAT GAT CGC GAA TGG CAT TTT TCA TGT GGT ACA AAG GAG	453
Gln His Val Tyr Asp Arg Glu Trp His Phe Ser Cys Gly Thr Lys Glu	
	100 105 110
TAC AAG GTT CTC ATG GAC CAG TTC CAT CAT GTA TCA ACT GCT TTT CTG	501
Tyr Lys Val Leu Met Asp Gln Phe His His Val Ser Thr Ala Phe Leu	
	115 120 125 130
GAG CTT AGG AAA CAT TAT CAG CAG GCA ATT GAG GAT ATT ACC ATG AGG	549
Glu Leu Arg Lys His Tyr Gln Gln Ala Ile Glu Asp Ile Thr Met Arg	
	135 140 145
ATG GGT GCA GGA ATG GCA AAA TTC ATA TGC AAG GAG GTG GAA ACA ACC	597
Met Gly Ala Gly Met Ala Lys Phe Ile Cys Lys Glu Val Glu Thr Thr	
	150 155 160

-33-

GAT Asp	GAT Asp	TAT Tyr	GAC Asp	GAA Glu	TAT Tyr	TGT Cys	CAC His	TAT Tyr	GTA Val	GCT Ala	GGG Gly	CTT Leu	GTT Val	GGG Gly	CTA Leu	645
		165					170					175				
GGA Gly	TTG Leu	TCA Ser	AAA Lys	CTG Leu	TTC Phe	CAT His	GCC Ala	TCT Ser	GAG Glu	AAA Lys	GAA Glu	GAT Asp	CTG Leu	GCT Ala	TCA Ser	693
	180					185					190					
GAT Asp	TCT Ser	CTC Leu	TCC Ser	AAC Asn	TCC Ser	ATG Met	GGT Gly	TTA Leu	TTT Phe	CTT Leu	CAG Gln	AAA Lys	ACA Thr	AAC Asn	ATC Ile	741
	195				200					205					210	
ATT Ile	AGA Arg	GAT Asp	TAT Tyr	TTG Leu	GAA Glu	GAC Asp	ATA Ile	AAT Asn	GAA Glu	GTA Val	CCC Pro	AAG Lys	TGC Cys	CGT Arg	ATG Met	789
				215					220					225		
TTC Phe	TGG Trp	CCC Pro	CGT Arg	GAA Glu	ATA Ile	TGG Trp	AGT Ser	AAA Lys	TAT Tyr	GTT Val	AAC Asn	AAG Lys	CTT Leu	GAG Glu	GAA Glu	837
			230					235						240		
TTA Leu	AAG Lys	TAC Tyr	GAG Glu	GAT Asp	AAC Asn	TCG Ser	GCC Ala	AAA Lys	GCA Ala	GTG Val	CAA Gln	TGT Cys	CTA Leu	AAT Asn	GAC Asp	885
		245					250					255				
ATG Met	GTC Val	ACT Thr	AAT Asn	GCT Ala	TTA Leu	TCA Ser	CAT His	GTA Val	GAA Glu	GAT Asp	TGT Cys	TTG Leu	ACT Thr	TAC Tyr	ATG Met	933
	260					265					270					
TCT Ser	GCT Ala	TTG Leu	CGT Arg	GAT Asp	CCT Pro	TCC Ser	ATC Ile	TTT Phe	CGA Arg	TTC Phe	TGT Cys	GCT Ala	ATT Ile	CCA Pro	CAG Gln	981
	275				280					285					290	
GTC Val	ATG Met	GCA Ala	ATT Ile	GGG Gly	ACA Thr	TTA Leu	GCT Ala	AGG Met	TGC Cys	TAC Tyr	GAC Asp	AAC Asn	ATT Ile	GAA Glu	GTC Val	1029
				295					300					305		
TTC Phe	AGA Arg	GGA Gly	GTG Val	GTA Val	AAA Lys	ATG Met	AGA Arg	CGT Arg	GGT Gly	CTG Leu	ACT Thr	GCT Ala	AAG Lys	GTC Val	ATT Ile	1077
			310					315					320			
GAC Asp	CGG Arg	ACC Thr	AGG Arg	ACT Thr	ATT Ile	GCA Ala	GAT Asp	GTA Val	TAT Tyr	GGT Gly	GCT Ala	TTT Phe	TTT Phe	GAC Asp	TTT Phe	1125
		325					330					335				
TCT Ser	TGT Cys	ATG Met	CTG Leu	AAA Lys	TCC Ser	AAG Lys	GTT Val	AAT Asn	AAT Asn	AAT Asn	GAT Asp	CCA Pro	AAT Asn	GCA Ala	ACA Thr	1173
	340					345					350					
AAA Lys	ACT Thr	CTG Leu	AAG Lys	AGG Arg	CTC Leu	GAA Glu	GTG Val	ATC Ile	CTG Leu	AAA Lys	ACT Thr	TGC Cys	AGA Arg	GAT Asp	TCG Ser	1221
	355				360					365					370	
GGA Gly	ACC Thr	TTG Leu	AAC Asn	AAA Lys	AGG Arg	AAA Lys	TCC Ser	TAC Tyr	ATA Ile	ATC Ile	AGG Arg	AGC Ser	GAG Glu	CCT Pro	AAT Asn	1269
				375					380					385		

- 34 -

TAC AGT CCA GTT CTG ATT GTT GTC ATT TTC ATC ATA CTG GCT ATT ATT	1317
Tyr Ser Pro Val Leu Ile Val Val Ile Phe Ile Ile Leu Ala Ile Ile	
390 395 400	
CTC GCA CAG CTA TCC GGA AAC CGA TCT TAGACGATAT TTTGGGTTAC	1364
Leu Ala Gln Leu Ser Gly Asn Arg Ser	
405 410	
AAAAAAGAAG TCTGGTCAAG GAAGACAGCA GAAGCTCTTG GCCAATTGTG TGATTAGTGC	1424
AGATTTTGAT GTTTGTAATT CTATCGTCCA TTAAGTGATA GTTGACCTT TTAACCTGAC	1484
AAGATAATTA CGAAGACCTA TTTTGGTGG TTTGTTGGGT ATGTACTTGT TTGCAAGGCT	1544
ACGTAAGCAA ATTCCAAGTG TTGTAGAGTC ACCGTGATGT AATAAACATG TCTTTTATTA	1604
TAGTTTGTTC ATTTTGTGG TAAAAA AAAA	1642

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 411 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Ser Leu Arg Ala Ile Leu Lys Asn Pro Glu Asp Leu Tyr Pro	
1 5 10 15	
Leu Val Lys Leu Lys Leu Ala Ala Arg His Ala Glu Lys Gln Ile Pro	
20 25 30	
Pro Ser Pro Asn Trp Gly Phe Cys Tyr Ser Met Leu His Lys Val Ser	
35 40 45	
Arg Ser Phe Ala Leu Val Ile Gln Gln Leu Pro Val Glu Leu Arg Asp	
50 55 60	
Ala Val Cys Ile Phe Tyr Leu Val Leu Arg Ala Leu Asp Thr Val Glu	
65 70 75 80	
Asp Asp Thr Ser Ile Pro Thr Asp Val Lys Val Pro Ile Leu Ile Ser	
85 90 95	
Phe His Gln His Val Tyr Asp Arg Glu Trp His Phe Ser Cys Gly Thr	
100 105 110	
Lys Glu Tyr Lys Val Leu Met Asp Gln Phe His His Val Ser Thr Ala	
115 120 125	
Phe Leu Glu Leu Arg Lys His Tyr Gln Gln Ala Ile Glu Asp Ile Thr	
130 135 140	

-35-

Met Arg Met Gly Ala Gly Met Ala Lys Phe Ile Cys Lys Glu Val Glu
 145 150 155 160
 Thr Thr Asp Asp Tyr Asp Glu Tyr Cys His Tyr Val Ala Gly Leu Val
 165 170 175
 Gly Leu Gly Leu Ser Lys Leu Phe His Ala Ser Glu Lys Glu Asp Leu
 180 185 190
 Ala Ser Asp Ser Leu Ser Asn Ser Met Gly Leu Phe Leu Gln Lys Thr
 195 200 205
 Asn Ile Ile Arg Asp Tyr Leu Glu Asp Ile Asn Glu Val Pro Lys Cys
 210 215 220
 Arg Met Phe Trp Pro Arg Glu Ile Trp Ser Lys Tyr Val Asn Lys Leu
 225 230 235 240
 Glu Glu Leu Lys Tyr Glu Asp Asn Ser Ala Lys Ala Val Gln Cys Leu
 245 250 255
 Asn Asp Met Val Thr Asn Ala Leu Ser His Val Glu Asp Cys Leu Thr
 260 265 270
 Tyr Met Ser Ala Leu Arg Asp Pro Ser Ile Phe Arg Phe Cys Ala Ile
 275 280 285
 Pro Gln Val Met Ala Ile Gly Thr Leu Ala Met Cys Tyr Asp Asn Ile
 290 295 300
 Glu Val Phe Arg Gly Val Val Lys Met Arg Arg Gly Leu Thr Ala Lys
 305 310 315 320
 Val Ile Asp Arg Thr Arg Thr Ile Ala Asp Val Tyr Gly Ala Phe Phe
 325 330 335
 Asp Phe Ser Cys Met Leu Lys Ser Lys Val Asn Asn Asn Asp Pro Asn
 340 345 350
 Ala Thr Lys Thr Leu Lys Arg Leu Glu Val Ile Leu Lys Thr Cys Arg
 355 360 365
 Asp Ser Gly Thr Leu Asn Lys Arg Lys Ser Tyr Ile Ile Arg Ser Glu
 370 375 380
 Pro Asn Tyr Ser Pro Val Leu Ile Val Val Ile Phe Ile Ile Leu Ala
 385 390 395 400
 Ile Ile Leu Ala Gln Leu Ser Gly Asn Arg Ser
 405 410

-36-

THAT WHICH IS CLAIMED IS:

1. An isolated nucleotide molecule encoding a polypeptide which has enzymatic activity for producing squalene, which nucleotide molecule is isolated from a *Nicotiana* species.

5

2. An isolated nucleotide molecule encoding a polypeptide which has enzymatic activity for producing squalene, which nucleotide molecule encodes a polypeptide having an amino acid sequence specified by SEQ ID NO:2.

10

3. An isolated nucleotide molecule encoding squalene synthetase selected from the group consisting of:

15

(a) isolated nucleotide molecules consisting essentially of the sequence specified by SEQ ID NO:1;

20

(b) isolated nucleotide molecules which hybridize to an isolated nucleotide molecule of (a) above under conditions represented by a wash stringency of 0.3M NaCl, 0.03M sodium citrate, and 0.1% SDS at 60°C, which are at least about 95% homologous to isolated nucleotide molecules of (a) above and which encode squalene synthetase; and

25

(c) isolated nucleotide molecules which differ in sequence from the isolated nucleotide molecules of (a) and (b) above due to the degeneracy of the genetic code, and which encode squalene synthetase.

30

4. The nucleotide molecule of Claim 1 in the form of DNA.

5. The nucleotide molecule of Claim 2 in the form of DNA.

-37-

6. The nucleotide molecule of Claim 3 in the form of DNA.


5 7. The nucleotide molecule of Claim 5 isolated from a *Nicotiana* species.

8. The nucleotide molecule of Claim 6 isolated from a *Nicotiana* species.

10 9. The nucleotide molecule of Claim 4 isolated from *Nicotiana benthamiana*.

15 10. The nucleotide molecule of Claim 5 isolated from *Nicotiana benthamiana*.

11. The nucleotide molecule of Claim 6 isolated from *Nicotiana benthamiana*.

**FIG. I.**

SUBSTITUTE SHEET (RULE 26)




FIG. 2.




FIG. 3.

SUBSTITUTE SHEET (RULE 26)




FIG. 4.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/11280

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/53, 15/29, 15/63, 15/70
US CL : 536/23.2, 23.6, 24.5; 435/320.1, 252.33
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.2, 23.6, 24.5; 435/320.1, 252.33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Molecular and Cellular Biology, Volume 13, Number 5, issued May 1993, G.W. Robinson et al, "Conservation between Human and Fungal Squalene Synthetases: Similarities in Structure, Function, and Regulation", pages 2706-2717, see especially pages 2708-2715 and Figures 5 and 6.	1-11
Y	Plant Physiology, Volume 8, Number 1, issued January 1992, K. Hanley et al, "Solubilization, Partial Purification, and Immunodetection of Squalene Synthetase from Tobacco Cell Suspension Cultures", pages 215-220, see entire article.	1-11
Y	US, A, 5,290,926 (SCHEIDEGGER ET AL) 01 March 1994, columns 3-25 and Figures 1 and 3A-D.	1-11

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 OCTOBER 1995

Date of mailing of the international search report

20 DEC 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WILLIAM W. MOORE

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/11280

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	The Journal of Biological Chemistry, Volume 267, Number 30, issued 25 October 1992, T. L. McKenzie et al, "Molecular Cloning, Expression, and Characterization of the cDNA for the Rat Hepatic Squalene Synthetase", pages 21368-21374, see especially pages 21369-21373 and Figures 5-8.	1-11
Y	Proceedings of the National Academy of Sciences, U.S.A., Volume 85, Number 23, issued December 1988, M. A. Frohman et al, "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer", pages 8988-9002, see entire article.	1, 4 and 9
Y	Journal of Molecular Biology, Volume 183, Number 1, issued 05 May 1985, R. Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations", pages 1-12, see entire article.	2, 3, 5-8, 10 and 11
Y	Nucleic Acids Research, Volume 19, Sequences Supplement, issued 25 April 1991, K. Wada et al, "Codon usage tabulated from the GenBank genetic sequence data", pages 1981-1986, see pages 1981 and 3rd column, "TOB", from left at page 1983.	2, 3, 5-8, 10 and 11
Y	Nucleic Acids Research, Volume 11, Number 8, issued 1983, M. Jaye et al, "Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX", pages 2325-2335, see pages 2326-2334 and compare Figures 1 and 4.	2, 4, 5-8, 10 and 11
A	GB, A, 2,249,099 (E.R. SQUIBB & SONS, INC.) 29 April 1992, pages 28-53 and Figures 2A-B and 4.	1-11
A	The Journal of Biological Chemistry, Volume 268, Number 17, issued 15 June 1993, G. Jiang et al, "Transcriptional Regulation by Lovastatin and 25-Hydroxycholesterol in HepG2 Cells and Molecular Cloning and Expression of the cDNA for the Human Hepatic Squalene Synthetase" pages 12818-12824.	1-11
A	Archives of Biochemistry and Biophysics, Volume 302, Number 1, issued April 1993, pages 304-306, R. K. Keller et al, "Identification and Regulation of Rat Squalene Synthetase mRNA", pages 304-306.	1-11
A	Secondary Metabolite Biosynthesis and Metabolism, issued 1992, Plenum Press, New York, R. J. Petroski et al, Editors, K. M. Hanley et al, "A Study of the Isoprenoid Pathway in Elicitor-Treated Tobacco Cell Suspension Cultures", pages 329-336.	1-11

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/11280

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Archives of Biochemistry and Biophysics, Volume 304, Number 1, issued July 1993, D. Zhang et al, "Yeast Squalene Synthase: Expression, Purification, and Characterization of Soluble Recombinant Enzyme", pages 133-143, especially pages 134-135 and 141-142.	1-11

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

SEQ ID NO:1 searched in N-GeneSeq 18, UEMBL 42-88, EMBL-NEW 5, GenBank 88 and GenBank-NEW 5; SEQ ID NO:2 searched in SwissProt 31, PIR 44 and A-GeneSeq 18; keyword search conducted in DIALOG Files Agricola, Biosis Previews, CA Search, Medline, Current Biotechnology Abstracts, Derwent Biotechnology Abstracts and Derwent World Patent Index

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)